This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma
J Natl Compr Canc Netw. 2020 Mar;18(3) :355-361
PMID: 32135514 URL: https://www.ncbi.nlm.nih.gov/pubmed/32135514
AbstractFive new PD-1/PD-L1 checkpoint inhibitors have been approved for the treatment of metastatic urothelial carcinoma (UC): pembrolizumab, atezolizumab, durvalumab, nivolumab, and avelumab. Although cisplatin-based chemotherapy remains the recommended frontline option for cisplatin-eligible patients with metastatic UC, immunotherapy is now an available option in the second-line setting as well as the frontline setting for selected cisplatin-ineligible patients who are either unable to tolerate chemotherapy or PD-L1-positive. This review describes the updated clinical efficacy of these checkpoint inhibitors in the treatment of advanced UC and suggests how they can be sequenced in the context of available chemotherapeutic options.
Notes1540-1413 Ghatalia, Pooja Plimack, Elizabeth R Journal Article Review United States J Natl Compr Canc Netw. 2020 Mar;18(3):355-361. doi: 10.6004/jnccn.2020.7539.